ZURICH, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) — Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare expertise firm that’s creating new improvements and disruptive diagnostic options that put individuals first, introduced right this moment that it’ll maintain a company replace webcast for all shareholders and buyers on Tuesday, November 22, 2022 at 9:00 am EST / 3:00 pm CET. A PowerPoint presentation will probably be obtainable on the time of the decision and revealed on the corporate web site at https://www.achiko.com/financials.
Details of webcast are as follows:
Find your native quantity: https://us02web.zoom.us/u/knHHcenwR
Recently, Achiko introduced that it’s commencing industrial deliveries of its Generation 2 AptameX™ Covid-19 take a look at equipment to Nahdlatul Ulama and different industrial purchasers, each beginning in and round Jakarta. Nahdlatul Ulama is the Jakarta department of Nahdlatul Ulama, which nationally in Indonesia has over 90 million registered members and operates over 6,000 faculties and universities, and a number of other hundred hospitals and clinics.
AptameX is the Company’s proprietary saliva-based Covid-19 take a look at using DNA aptamers sure to gold nanoparticles in a colloidal resolution. The result’s learn by a UV Spectrophotometer after which analyzed with customized software program. Unlike a molecular and immunoassay approaches, the take a look at’s use of DNA aptamers has yielded encouraging outcomes at low viral masses outperforming most lateral movement based mostly speedy assessments.
ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is creating disruptive diagnostic options that put individuals first. The Company’s lead product, AptameX™, is a speedy, dependable Covid-19 take a look at with a companion app, Teman Sehat™, providing a user-friendly digital well being passport. AptameX™ and Teman Sehat™ had been launched in Indonesia in mid-2021 and AptameX™ acquired the CE Mark within the European Union in May 2022.
The AptameX™ DNA aptamer assessments will be quickly chemically synthesized, are cost-effective, simply scalable and have broad potential throughout a number of illness areas. Achiko goals to ship quick, correct and reasonably priced diagnostic testing for a spread of ailments within the quickly evolving healthcare diagnostics discipline.
Headquartered in Zurich, Achiko has workplaces in Jakarta, and workers all over the world.
Media contacts:
ACHIKO AG
Investor Relations
E: [email protected]
Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: [email protected]
T: +41 44 266 67 67
DISCLAIMER
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain oknown and unoknown dangers, uncertainties, and other factors, whelloch could trigger the actual outcomes, financial condition, performance or achievements of Achiko AG to be materialsly different from any future outcomes, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is offering this communication as of this date and does not undertake to update any forward-looking statements includeed herein as a end result of new information, future events or otherwise.
